Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.

Hepatology (Baltimore, Md.) - 1 Aug 2023

Fernandez-Antunez Carlota, Wang Kuan, Fahnøe Ulrik, Mikkelsen Lotte S, Gottwein Judith M, Bukh Jens, Ramirez Santseharay

Abstract excerpt

BACKGROUND AND AIMS: The high HCV infection cure rates achieved with direct-acting antiviral (DAA) treatments could be compromised in the future by the emergence of antiviral resistance. Thus, it is essential to understand the viral determinants that influence DAA resistance, which is most prevalent in genotype 3. We aimed at studying how resistance to protease-, NS5A-, and NS5B-inhibitors influences the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 36999539
DOI: 10.1097/HEP.0000000000000353

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.PMID 36999539Read ↗

Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.Semantic proximity Read ↗

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.Semantic proximity Read ↗

Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Resistance to direct antiviral agents in patients with hepatitis C virus infection.Semantic proximity Read ↗

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Semantic proximity Read ↗

Treatment failure with DAA therapy: Importance of resistance.Semantic proximity Read ↗

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.Semantic proximity Read ↗

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.Semantic proximity Read ↗

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting AntiviralsSemantic proximity Read ↗

A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.Semantic proximity Read ↗

The emerging field of HCV drug resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.